HomeNewsBusinessReal EstateCOVID-19 impact: Financial challenges faced by real estate developers

COVID-19 impact: Financial challenges faced by real estate developers

The lockdown was preceded by flattening sales in the residential segment while developers with commercial, retail, warehousing, or hospitality assets saw a growth phase with increased investment activity.

April 11, 2021 / 13:24 IST
Story continues below Advertisement

The real estate sector was caught in a conundrum last year with flattening demand, a challenging funding environment, and increasing compliance-based costs. The onset of the pandemic exposed the fragile financial health and business models of real estate developers in India. The financial health of developers in the preceding 12 months can be seen in two parts – the lockdown phase and the unlocking phase.

Lockdown phase:

Story continues below Advertisement

The lockdown was preceded by flattening sales in the residential segment while developers with commercial, retail, warehousing, or hospitality assets saw a growth phase with increased investment activity. However, the impact of the pandemic was such that all segments saw a sudden contraction in the activity. This can be witnessed in a drop of 23.0% in institutional capital inflow into India (while credit offtake as per RBI statistics registered a growth of only 0.25% in H1 2020 after 1.5% growth M-o-M in FY 2019-20. This reflects the challenging conditions both on the compliance side and risk attributed to the sector. Apart from Grade A developers and developers with a good credit track record, many struggled to attain financial closures and raise capital.

Cashflow issues compounded this issue for developers due to a drop in collections from pre-sold stock, loss of demand for existing or new supply, and pressure to keep with debt repayments till relaxation was announced in May 2020.  Intense lockdown for a period of 60 days took a toll on marketing, requiring additional investments into online marketing models while yield generating assets suddenly saw active renegotiations or a drop in rental revenues. This issue was compounded in assets like malls which until Q1 2020 saw active institutional investments. These issues led to significant erosion of value in underwritten assets for banks, NBFCs, and returns fell for equity investors urging capital flight to assets that proved to be resilient to the pandemic like warehousing and Grade A commercial projects. This is reflected in the fact that commercial and warehousing assets had institutional capital investments same as 2019 while the residential segment fell by 60% and hospitality saw a drop of more than 80%.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show